Bristol-Myers CEO Says Diversified Product Line Driving Growth -- Market Talk

Dow Jones01-13

1339 ET - Bristol-Myers Squibb has a diversified set of products driving revenue, Chief Executive Officer Chris Boerner says at the JPMorgan Healthcare Conference. "Our future growth will not be dependent on one or two blockbuster products," Boerner says. He says Bristol-Myers now has four products that are annualizing with sales of over a $1 billion each. The group includes Opdualag, Breyanzi, Camzyos--and he says Reblozyl, an anemia treatment, is annualizing to over $2 billion in sales. "Each of these products continues to be a core element of how we're going to grow the company and each has good momentum coming into this year." (elias.schisgall@wsj.com)

(END) Dow Jones Newswires

January 12, 2026 13:39 ET (18:39 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603252857?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 02:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603252857","market":"sh","top_or_hot":-1,"title":"Bristol-Myers CEO Says Diversified Product Line Driving Growth -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1339 ET - <a href=\"https://laohu8.com/S/BMYMP\">Bristol-Myers Squibb</a> has a diversified set of products driving revenue, Chief Executive Officer Chris Boerner says at the JPMorgan Healthcare Conference. \"Our future growth will not be dependent on one or two blockbuster products,\" Boerner says. He says Bristol-Myers now has four products that are annualizing with sales of over a $1 billion each. The group includes Opdualag, Breyanzi, Camzyos--and he says Reblozyl, an anemia treatment, is annualizing to over $2 billion in sales. \"Each of these products continues to be a core element of how we're going to grow the company and each has good momentum coming into this year.\" (elias.schisgall@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 13:39 ET (18:39 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol-Myers CEO Says Diversified Product Line Driving Growth -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol-Myers CEO Says Diversified Product Line Driving Growth -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-13 02:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1339 ET - <a href=\"https://laohu8.com/S/BMYMP\">Bristol-Myers Squibb</a> has a diversified set of products driving revenue, Chief Executive Officer Chris Boerner says at the JPMorgan Healthcare Conference. \"Our future growth will not be dependent on one or two blockbuster products,\" Boerner says. He says Bristol-Myers now has four products that are annualizing with sales of over a $1 billion each. The group includes Opdualag, Breyanzi, Camzyos--and he says Reblozyl, an anemia treatment, is annualizing to over $2 billion in sales. \"Each of these products continues to be a core element of how we're going to grow the company and each has good momentum coming into this year.\" (elias.schisgall@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 13:39 ET (18:39 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYE","symbol_name":"Myers Industries Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603252857","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603252857","pubTimestamp":1768243140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1339 ET - Bristol-Myers Squibb has a diversified set of products driving revenue, Chief Executive Officer Chris Boerner says at the JPMorgan Healthcare Conference. \"Our future growth will not be dependent on one or two blockbuster products,\" Boerner says. He says Bristol-Myers now has four products that are annualizing with sales of over a $1 billion each. The group includes Opdualag, Breyanzi, Camzyos--and he says Reblozyl, an anemia treatment, is annualizing to over $2 billion in sales. \"Each of these products continues to be a core element of how we're going to grow the company and each has good momentum coming into this year.\" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MYE":"Myers Industries Inc","BK4126":"金属与玻璃容器"},"translate_title":"百时美施贵宝首席执行官表示多元化产品线推动增长——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYE":1.5},"content_text":"1339 ET - Bristol-Myers Squibb has a diversified set of products driving revenue, Chief Executive Officer Chris Boerner says at the JPMorgan Healthcare Conference. \"Our future growth will not be dependent on one or two blockbuster products,\" Boerner says. He says Bristol-Myers now has four products that are annualizing with sales of over a $1 billion each. The group includes Opdualag, Breyanzi, Camzyos--and he says Reblozyl, an anemia treatment, is annualizing to over $2 billion in sales. \"Each of these products continues to be a core element of how we're going to grow the company and each has good momentum coming into this year.\" (elias.schisgall@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  January 12, 2026 13:39 ET (18:39 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603252857","isCrawlerRequest":true}